Background: Dimethyl fumarate is an oral treatment for multiple sclerosis, whose mechanism of action is not fully understood. Objective: To investigate the effects of dimethyl fumarate on DNA methylation in the CD4 þ T cells of multiple sclerosis patients. Methods: We performed Illumina EPIC arrays to investigate the DNA methylation profiles of CD4 þ T cells derived from multiple sclerosis patients before and after dimethyl fumarate treatment. Results: Treatment with dimethyl fumarate resulted in 97% of differentially methylated positions showing hypermethylation. Four genes, SNORD1A, SHTN1, MZB1 and TNF had a differentially methylated region located within the transcriptional start site. Conclusion: This study investigates the effect of dimethyl fumarate on DNA methylation in multiple sclerosis patients.
Introduction
Although increasing numbers of treatments are available for multiple sclerosis (MS), the exact mechanism of action of these therapies is often unclear. Patients are frequently required to trial several treatments to identify which is most suitable for their disease activity. Dimethyl fumarate (DMF; Tecfidera, Biogen Idec, Cambridge MA, USA) is approved in Europe and Australia as a first-line oral drug for the treatment of relapsing-remitting multiple sclerosis, and its use is associated with a reduction in disease activity and a variable effect on progression. 1, 2 Although the exact mode of action is not fully elucidated, DMF has been shown to have both antiinflammatory and anti-oxidative properties. Decreased absolute lymphocyte counts and a shift in T lymphocyte polarisation from T helper (Th)1 and Th17 (pro-inflammatory) to Th2 phenotype (anti-inflammatory) has been reported after DMF treatment in MS patients. 3 DMF also promotes translocation of nuclear factor erythroid 2-related factor 2 into the nucleus, which upregulates the transcription of anti-oxidative enzymes. 3 DNA methylation refers to the epigenetic modification whereby the addition/removal of methyl groups to CpG dinucleotides regulates gene transcription. We, and others, have assessed global methylation profiles in CD4 þ and CD8 þ T cells from MS patients compared to healthy controls. [4] [5] [6] Our studies have demonstrated altered methylation profiles in the CD4 þ T cells of treatment-naive patients or in the absence of treatment. However, the effect of disease-modifying therapies (DMTs) on methylation profiles remains unclear. Neither group found significant changes in CD8 þ T cells. 5, 6 Here we performed a longitudinal study of the genome-wide methylation profiles of CD4 þ T cells in MS patients before and after DMF treatment.
Methods
We recruited seven MS patients (three men and four women) who were either treatment naive or had been off DMT for at least 3 months and were planning to start DMF therapy ( Table 1 ). The majority of patients had not had steroid use for at least 2 months prior to entry into this study (Table 1 ). Samples were collected and processed as previously described. 7 Blood was collected prior to the first dose of DMF and 6 months following treatment initation. At 6 months, all patients remained on therapy and had no change in Expanded Disability Status Score (EDSS). Two patients had evidence of disease activity as assessed by the appearance of new lesions on magnetic resonance imaging (MRI). However, both of these patients showed no new disease activity at their next MRI and remain on therapy.
CD4 þ T cells were extracted using magnetic isolation kits (Stem Cell Technologies, Canada) and purity (mimimum threshold !90%) was assessed using the FACS CantoII (BD Biosciences) system. Purified DNA was bisulphite converted and hybridised to Illumina EPIC arrays. Raw fluorescence data were processed using a combination of R/ Bioconductor and custom scripts. Differences in mean methylation before and after the 6-month treatment period were tested using a paired samples t-test for each CpG. A CpG was considered a differentially methylated position (DMP) if the P value was less than 0.0005 and the absolute difference in mean methylation between groups was greater than 5%. A differentially methylated region (DMR) was defined as two or more contiguous DMPs located within 500 bp of each other, whose methylation changes were in the same direction. If a DMP was located outside of the 500 bp region but was less than 500 bp from the last DMP it was also included in the DMR.
Results and discussion
In total, 945 DMPs were identified when comparing the 6-month time point to baseline, the majority of which were hypermethylated after treatment (912; 97%) (see Supplementary Table 1 ). The most altered DMP between baseline and treatment was 17.5% hypermethylated (cg14048158); however, this site maps to an area with no known gene association. To identify sites of potential functional consequence, we filtered DMPs to include only those with a DMR, gene name and position annotation. Table 2 shows the DMPs with the largest percentage change for each of the resulting 64 genes.
Four genes had at least two adjacent DMPs located in the transcriptional start site (TSS) ( Table 3) . SNORD1A (small nucleolar RNA, C/D box 1A) encodes for an uncharacterised small nucleolar RNA. SHTN1 encodes shootin1, a protein involved in neuronal polarisation of axons. 8 MZB1 (marginal zone B and B1 cell-specific protein) codes for an endoplasmic reticulum calcium regulator. While it has not previously been linked to MS, a study by Belkaya et al. (2013) found that overexpression of miR-185 resulted in a nearly five-fold decrease of MZB1 in mice. 9 This decrease corresponded with lymphopenia and a reduced proliferative response in CD4 þ T cells. 9 The observed increase in DNA methylation identified in the MZB1 TSS in our dataset may result in a similar decrease in MZB1 transcription. A resulting decrease in CD4 þ T cells would be consistent with the known anti-inflammatory action of DMF.
The fourth DMR identified is located at the TSS of tumour necrosis factor (TNF). TNF is a proinflammatory cytokine that is produced by many cell types, including lymphocytes (reviewed in Wajant et al). 10 TNF binding to its receptor activates the nuclear factor kappa B (NF-jB) pathway, which activates the transcription of genes involved in cell survival and proliferation, inflammatory response and anti-apoptotic factors. Hypermethylation at the TNF TSS may result in decreased TNF production, and a decrease in activation of the NF-jB pathway. One known mechanism of action for DMF is preventing translocation of NF-jB to the nucleus, resulting in a decrease of pro-inflammatory cytokines and an increase of anti-inflammatory cytokines (reviewed in Pistono et al.). 3 It is possible that altered DNA methylation profiles at the TNF TSS may contribute to this mechanism. DMF has previously been linked to other epigenetic mechanisms in a study by Kalinin et al. (2013) , in which they reported that DMF increased expression of histone deacetylases in cultured rat astrocytes. 11 Both DNA methylation and histone deacetylation are associated with gene repression. 12 Taken together there is now evidence that DMF may act as an epigenetic modifier with the function of shutting down transcription associated with proinflammatory activity.
One limitation of this study is that we only assessed patients who started DMF treatment. Also, athough the majority of patients were stable at the time of baseline collection, two patients had recently had a relapse, only one of whom was treated with steroids. We are therefore unable to determine for certain if the changes in methylation profiles are due to treatment effects or stabilisation of disease. Future studies comparing changes following different therapies and different disease severities are required. A further limitation is the small sample size and lack of transcriptional data. Future studies characterising treatment responses in larger populations that also investigate the functional changes at the transcriptional level are warranted. This is the first longitudinal study to investigate the effect of DMF on the DNA methylation of CD4 þ T cells of MS patients. Of the most interest, the DMRs identified at TNF and MZB1 provide a potential novel mechanism of action for DMF. Treatment with DMF resulted in overall hypermethylation suggesting that DMF may act to promote DNA methylation. Larger studies are warranted to elucidate further the functional link between DMF and epigenetic mechanisms.
